Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Definium Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 8 | 156 | +148 |
| Shares | 294.2K | 37.8M | +37.5M (+12,753.2%) |
| Value | $932.0K | $131.0M | +$130.1M (+13,959.7%) |
New holders (149)
Institutions that held Definium Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Showing the largest 100 of 149 by value.
Sold out (1)
Institutions that held Definium Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Canton Hathaway, LLC | 1,000 | $3.00K |